This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion. This marks the lowest recorded annual investment in more than a decade. While investments toward research in preventive vaccines, PrEP and medical male circumcision increased in 2016, funding for microbicides, treatment as prevention, female condoms and prevention of vertical transmission decreased.
HIV Prevention Research & Development Investments, 2000–2016: Investment priorities to fund innovation in a challenging global health landscape
Global Investment in HIV Cure Research and Development in 2016: Funding for a cure remains a priority
Don’t miss this report looking at investment in cure research in 2016. It’s part of the annual report on investment in research and development that AVAC produces as a member of the Resource Tracking for HIV Prevention Research & Development Working Group.
Hormonal Contraceptive Methods and HIV: Research gaps and programmatic priorities
This article in Contraception summarizes key findings and conclusions from a December 2015 meeting convened by WHO on the research agenda for hormonal contraception and HIV.
HIV Prevention Trial Terms: An advocate’s guide
This lexicon explains some of the terms used to talk about trials designed to test new HIV prevention tools.
Advocacy in Uncertain Times: A call to action
AVAC’s report for HIV Vaccine Awareness Day on the state of the HIV vaccine research and development field, including key priorities for advancing research and sustaining support.
Financing the Search: Then and now
Funding for vaccines research in 1997 and 2016, segmented by government and other sector spending.
Number of Vaccines Trials: Then and now
A snapshot of the number of vaccine trials conducted globally between 1997 and 2017.
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.